Last week, I took a closer look at outside days on a candlestick chart of the S&P 500 Index (SPX). As a refresher, an outside day occurs when a stock’s daily high is higher than the prior day’s high, and its low is lower than the prior day's low. Essentially, it engulfs the prior day's range. In that article, I broke down when outside days tend to be more meaningful instead of just noise. This week, I’m applying the same analysis to individual stocks within the S&P 500. By the end, I find a setup that stand ...

About this content About Oliver Haill Oliver has been writing about companies and markets since the early 2000s, cutting his teeth as a financial journalist at Growth Company Investor with a focusing on AIM companies and small caps, before a few years later becoming a section editor and then head of research. He joined Proactive after a couple of years freelancing, where he worked for the Financial Times Group, ITV, Press Association, Reuters sports desk, the London Olympic News Service, Rugby World Cup ...

Heinz ketchup is displayed on shelves at a Walmart SuperCenter on August 02, 2023 in Austin, Texas.Kraft Heinz is spending $3 billion to upgrade its U.S. factories, its largest investment in its plants in a decade, even as executives say consumer sentiment is at its second-lowest point in 70 years, and it has cut sales and profit forecasts.The upgrades will help lower costs by making the plants more efficient, which in turn may help offset President Donald Trump's tariffs, which factored into the company's ...

Oliver Rodzianko is a macro-focused investment analyst with a global perspective and a focus on public equity strategy. His approach is grounded in valuation discipline and long-term fundamentals, with emphasis on sectors including technology, semiconductors, AI, and energy. He is U.S.-market centered, with international awareness informing his process. He manages a long-only, unleveraged portfolio designed to preserve capital and capture asymmetric upside around key market dislocations. Positions are held ...

Archer Aviation TodayACHRArcher Aviation$11.17 +2.09 (+23.02%) 52-Week Range$2.82▼$12.48Price Target$11.61Add to WatchlistArcher Aviation NYSE: ACHR delivered a positive first-quarter 2025 financial report on May 12, 2025, surpassing analyst expectations for earnings per share (EPS) and showcasing an improved net loss. Perhaps most notably for investors, the electric vertical takeoff and landing (eVTOL) aircraft developer confirmed its cash position now exceeds the crucial $1 billion threshold.Get Archer A ...

Interconnector project will accelerate Australia's renewable energy economySupports reliable transmission of electricity and telecommunications between Tasmania and VictoriaDALLAS, May 14, 2025 /PRNewswire/ -- Jacobs (NYSE: J) was selected as the Integrated Delivery Partner for Marinus Link, an approximately 214 mile (345-kilometer) undersea and underground high-voltage direct current (HVDC) electricity and data interconnector designed to bolster energy security, promote renewable energy investment and deli ...

ZYNLONTA® plus glofitamab (COLUMVI®) demonstrated ORR of 95.5% and CR of 90.9%, among 22 evaluable patients with relapsed/refractory DLBCLSafety and tolerability data were consistent with the known profiles of each agentUpdated data to be shared during poster presentation at EHA2025 on Saturday, June 14 at 12:30 p.m. ET and oral presentation at ICML on Friday, June 20 at 9:00 a.m. ETLAUSANNE, Switzerland, May 14, 2025 /PRNewswire/ -- ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pio ...

Summary⚈ ZIM offers a sky-high 41.73% dividend yield, attracting income investors.⚈ Strong fundamentals support recent gains, but risks remain due to industry volatility.⚈ Analysts expect a potential 20% stock drop despite upcoming earnings growth.Cargo company ZIM Integrated Shipping Services (NYSE: ZIM) has the highest annual dividend yield, 41.73%, which is attractive to income-seeking investors.Currently offering a quarterly dividend of $1.79, ZIM’s share price has surged more than 20% in the past month ...

Telefonica, S.A. (NYSE:TEF) Q1 2025 Earnings Conference Call May 14, 2025 4:00 AM ET Company Participants Torsten Achtmann - Director of IR Emilio Rodriguez - COO Laura Abasolo - CFO and Control Officer Lutz Schuler - CEO Virgin Media O2 Markus Haas - CEO of Telefonica Deutschland Conference Call Participants Andrew Lee - Goldman Sachs Mathieu Robilliard - Barclays Fernando Cordero Barreira - Banco Santander Akhil Dattani - JPMorgan James Ratzer - New Street Research Keval Khiroya - Deutsche Bank Operator ...

Core Viewpoint - Allogene Therapeutics reported a first-quarter 2025 loss of 28 cents per share, which aligns with the Zacks Consensus Estimate, showing an improvement from a loss of 38 cents per share in the same period last year [1] Financial Performance - The company did not report any sales during the quarter, as it lacks a marketed product, compared to collaboration revenues of $0.02 million in the year-ago period [1] - Research and development (R&D) expenses were $50.2 million, down 4% year over year, while general and administrative (G&A) expenses decreased by 13% to $15.0 million [5] - As of March 31, 2025, Allogene had $335.5 million in cash, cash equivalents, and investments, down from $373.1 million as of December 31, 2024 [5] 2025 Guidance - Allogene revised its 2025 guidance, expecting operating expenses to be around $230 million, including nearly $45 million in non-cash stock-based compensation, an improvement from the previous forecast of $250 million [6] - Cash burn for 2025 is now expected to be around $150 million, reduced from the previous guidance of $170 million, allowing the company to extend its cash runway into the second half of 2027 [7] Pipeline Updates - The pivotal phase II ALPHA3 study is evaluating lead drug cema-cel for treating newly diagnosed large B cell lymphoma patients, with the timeline for analysis pushed back to the first half of 2026 [9] - Allogene plans to initiate the phase I RESOLUTION basket study with ALLO-329 for autoimmune diseases in mid-2025, with the first data readout now expected in the first half of 2026 [10] - Updated data from the phase I TRAVERSE study evaluating ALLO-316 in advanced renal cell carcinoma will be presented at the 2025 ASCO Annual Meeting on June 1 [11] Stock Performance - Year to date, Allogene's shares have declined by 47%, contrasting with a 6% decline in the industry [2]